LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.

Hohmann FP, Laven JS, Mulders AG, Oberyé JJ, Mannaerts BM, de Jong FH, Fauser BC

Journal of endocrinological investigation1 Dec 2005Cited by 4 (Europe PMC)

PMID16483177DOI10.1007/bf03345337PepBankPUB-16483177

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanRandomized controlled trialEfficacy outcome
In PCOS patients, significant LH suppression with repeated ganirelix was comparable between the different doses.
In plain wordsIn PCOS patients, LH suppression with repeated ganirelix was comparable between the different doses.
Peptide
Ganirelix
Outcome
Direction not reportedLH suppression across doses
Study
n = 24
Comparator
other ganirelix doses
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.125, 0.250 or 0.500 mg daily · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Repeated GnRH antagonist administration induced a significant suppression of LH (and to a lesser extent of FSH) serum levels, which was comparable between the different doses.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317707
02HumanRandomized controlled trialEfficacy outcome
In PCOS patients, FSH suppression with repeated ganirelix was comparable between doses and less marked than LH suppression.
In plain wordsIn PCOS patients, FSH suppression with repeated ganirelix was comparable between doses and less marked than LH suppression.
Peptide
Ganirelix
Outcome
Direction not reportedFSH suppression across doses
Study
n = 24
Comparator
other ganirelix doses
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.125, 0.250 or 0.500 mg daily · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Repeated GnRH antagonist administration induced a significant suppression of LH (and to a lesser extent of FSH) serum levels, which was comparable between the different doses.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317708
03HumanNon-randomized trialEfficacy outcome
In PCOS patients, ganirelix reduced LH for 12 h, with levels returning to baseline at 24 h.
In plain wordsIn PCOS patients, ganirelix reduced LH for 12 h, with levels returning to baseline at 24 h.
Peptide
Ganirelix
Outcome
MixedDuration of LH suppression
Study
n = 24
Comparator
baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.125, 0.250 or 0.500 mg daily · subcutaneous · 7 daysAs given in this study (human).
Measurements
Duration of LH suppression
12 h
after drug administration
Time to return to baseline
24 h
after drug administration
Source sentences
Summary
The decrease in serum LH and FSH levels was transient and lasted for 12 h, after which serum levels returned to baseline levels at 24 h after drug administration.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317709
04HumanNon-randomized trialEfficacy outcome
In PCOS patients, ganirelix reduced FSH for 12 h, with levels returning to baseline at 24 h.
In plain wordsIn PCOS patients, ganirelix reduced FSH for 12 h, with levels returning to baseline at 24 h.
Peptide
Ganirelix
Outcome
MixedDuration of FSH suppression
Study
n = 24
Comparator
baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.125, 0.250 or 0.500 mg daily · subcutaneous · 7 daysAs given in this study (human).
Measurements
Duration of FSH suppression
12 h
after drug administration
Time to return to baseline
24 h
after drug administration
Source sentences
Summary
The decrease in serum LH and FSH levels was transient and lasted for 12 h, after which serum levels returned to baseline levels at 24 h after drug administration.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317710
05HumanNon-randomized trialEfficacy outcome
In PCOS patients, ganirelix did not significantly suppress androgen levels.
In plain wordsIn PCOS patients, ganirelix did not significantly reduce androgen levels compared with baseline.
Peptide
Ganirelix
Outcome
No significant changeAndrogen suppression
Study
n = 24
Comparator
baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.125, 0.250 or 0.500 mg daily · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Androgen levels were not significantly suppressed using this regimen.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317711
06HumanNon-randomized trialEfficacy outcome
In PCOS patients, ganirelix significantly reduced E2 levels (p < 0.001), with the strongest suppression at 0.500 mg daily.
In plain wordsIn PCOS patients, ganirelix reduced E2 versus baseline, with the strongest suppression at 0.500 mg daily.
Peptide
Ganirelix
Outcome
DecreaseEstradiol suppression
Study
n = 24
Comparator
baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.125, 0.250 or 0.500 mg daily · subcutaneous · 7 daysAs given in this study (human).
Measurements
p value
< 0.001
E2 decrease
Source sentences
Summary
E2 levels decreased significantly (p < 0.001) and suppression was most pronounced in Group C.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317712
07HumanNon-randomized trialEfficacy outcome
In PCOS patients receiving ganirelix, spontaneous follicle development was not recorded during treatment.
In plain wordsIn PCOS patients receiving ganirelix, spontaneous follicle development was not recorded during treatment.
Peptide
Ganirelix
Outcome
Not applicableSpontaneous follicle development
Study
n = 24
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.125, 0.250 or 0.500 mg daily · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Spontaneous follicle development or ovulations were not recorded during the course of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317713
08HumanNon-randomized trialEfficacy outcome
In PCOS patients receiving ganirelix, ovulations were not recorded during treatment.
In plain wordsIn PCOS patients receiving ganirelix, ovulations were not recorded during treatment.
Peptide
Ganirelix
Outcome
Not applicableOvulation
Study
n = 24
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.125, 0.250 or 0.500 mg daily · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Spontaneous follicle development or ovulations were not recorded during the course of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317714
09HumanNon-randomized trialEfficacy outcome
In PCOS patients, ganirelix 0.125 mg suppressed endogenous LH by 49% six hours after administration.
In plain wordsIn PCOS patients, ganirelix 0.125 mg reduced LH by 49% six hours after administration compared with baseline.
Peptide
Ganirelix
Outcome
DecreaseLH suppression at six hours
Study
n: not reported in source
Comparator
baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.125 mg daily · subcutaneous · 7 daysAs given in this study (human).
Measurements
LH suppression at 6 h
49%
0.125 mg group (Group A)
Source sentences
Summary
Six hours after ganirelix administration, endogenous LH was suppressed by 49, 69 and 75%, and endogenous FSH was suppressed by 23, 19 and 25%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317701
10HumanNon-randomized trialEfficacy outcome
In PCOS patients, ganirelix 0.250 mg suppressed endogenous LH by 69% six hours after administration.
In plain wordsIn PCOS patients, ganirelix 0.250 mg reduced LH by 69% six hours after administration compared with baseline.
Peptide
Ganirelix
Outcome
DecreaseLH suppression at six hours
Study
n: not reported in source
Comparator
baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.250 mg daily · subcutaneous · 7 daysAs given in this study (human).
Measurements
LH suppression at 6 h
69%
0.250 mg group (Group B)
Source sentences
Summary
Six hours after ganirelix administration, endogenous LH was suppressed by 49, 69 and 75%, and endogenous FSH was suppressed by 23, 19 and 25%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317702
11HumanNon-randomized trialEfficacy outcome
In PCOS patients, ganirelix 0.500 mg suppressed endogenous LH by 75% six hours after administration.
In plain wordsIn PCOS patients, ganirelix 0.500 mg reduced LH by 75% six hours after administration compared with baseline.
Peptide
Ganirelix
Outcome
DecreaseLH suppression at six hours
Study
n: not reported in source
Comparator
baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.500 mg daily · subcutaneous · 7 daysAs given in this study (human).
Measurements
LH suppression at 6 h
75%
0.500 mg group (Group C)
Source sentences
Summary
Six hours after ganirelix administration, endogenous LH was suppressed by 49, 69 and 75%, and endogenous FSH was suppressed by 23, 19 and 25%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317703
12HumanNon-randomized trialEfficacy outcome
In PCOS patients, ganirelix 0.125 mg suppressed endogenous FSH by 23% six hours after administration.
In plain wordsIn PCOS patients, ganirelix 0.125 mg reduced FSH by 23% six hours after administration compared with baseline.
Peptide
Ganirelix
Outcome
DecreaseFSH suppression at six hours
Study
n: not reported in source
Comparator
baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.125 mg daily · subcutaneous · 7 daysAs given in this study (human).
Measurements
FSH suppression at 6 h
23%
0.125 mg group (Group A)
Source sentences
Summary
Six hours after ganirelix administration, endogenous LH was suppressed by 49, 69 and 75%, and endogenous FSH was suppressed by 23, 19 and 25%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317704
13HumanNon-randomized trialEfficacy outcome
In PCOS patients, ganirelix 0.250 mg suppressed endogenous FSH by 19% six hours after administration.
In plain wordsIn PCOS patients, ganirelix 0.250 mg reduced FSH by 19% six hours after administration compared with baseline.
Peptide
Ganirelix
Outcome
DecreaseFSH suppression at six hours
Study
n: not reported in source
Comparator
baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.250 mg daily · subcutaneous · 7 daysAs given in this study (human).
Measurements
FSH suppression at 6 h
19%
0.250 mg group (Group B)
Source sentences
Summary
Six hours after ganirelix administration, endogenous LH was suppressed by 49, 69 and 75%, and endogenous FSH was suppressed by 23, 19 and 25%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317705
14HumanNon-randomized trialEfficacy outcome
In PCOS patients, ganirelix 0.500 mg suppressed endogenous FSH by 25% six hours after administration.
In plain wordsIn PCOS patients, ganirelix 0.500 mg reduced FSH by 25% six hours after administration compared with baseline.
Peptide
Ganirelix
Outcome
DecreaseFSH suppression at six hours
Study
n: not reported in source
Comparator
baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.500 mg daily · subcutaneous · 7 daysAs given in this study (human).
Measurements
FSH suppression at 6 h
25%
0.500 mg group (Group C)
Source sentences
Summary
Six hours after ganirelix administration, endogenous LH was suppressed by 49, 69 and 75%, and endogenous FSH was suppressed by 23, 19 and 25%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four PCOS patients with elevated endogenous LH concentrations were randomized into 3 different dose groups, receiving either 0.125 mg (Group A), 0.250 mg (Group B) or 0.500 mg (Group C) ganirelix sc daily for 7 subsequent days.
Report a problemFND-1648317706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.